Keeping Track: Pediatric Approvals, Seres Starts C Diff Submission, And BMS Pulls Reblozyl sBLA Before Possible CRL

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Keeping Track Feature image

One of the most interesting regulatory events last week is one that didn’t happen: Bristol Myers Squibb Company pulled an sBLA for Reblozyl ahead of its user fee goal date, avoiding a complete response letter.

Pediatrics were a common theme in the agency’s approvals. Ongoing efforts to improve treatment of pediatric organ transplant recipients resulted...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers